The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Key takeaways from ASCO 2022
Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, talks on key takeaways from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the Phase III DESTINY-Breast04 (NCT03734029) trial, which demonstrated a survival benefit with trastuzumab deruxtecan versus chemotherapy in patients with HER2-low breast cancer. Dr Whitworth also mentions the Phase II trial (NCT04165772) exploring the induction of PD-1 blockade in subjects with locally advanced mismatch repair deficient locally advanced rectal cancer, which demonstrated a highly impressive 100% complete response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
